69 related articles for article (PubMed ID: 18852281)
1. A dinucleotide motif in oligonucleotides shows potent immunomodulatory activity and overrides species-specific recognition observed with CpG motif.
Kandimalla ER; Bhagat L; Zhu FG; Yu D; Cong YP; Wang D; Tang JX; Tang JY; Knetter CF; Lien E; Agrawal S
Proc Natl Acad Sci U S A; 2003 Nov; 100(24):14303-8. PubMed ID: 14610275
[TBL] [Abstract][Full Text] [Related]
2. Alpha(α)-2 Receptor Agonists in Palliative Care.
Boanca K; Borris J; Noufi P
J Palliat Med; 2024 Apr; ():. PubMed ID: 38686515
[No Abstract] [Full Text] [Related]
3. Toll-like receptor agonists as cancer vaccine adjuvants.
Jeon D; Hill E; McNeel DG
Hum Vaccin Immunother; 2024 Dec; 20(1):2297453. PubMed ID: 38155525
[TBL] [Abstract][Full Text] [Related]
4. Intratumoural immunotherapy: activation of nucleic acid sensing pattern recognition receptors.
Agrawal S; Kandimalla ER
Immunooncol Technol; 2019 Oct; 3():15-23. PubMed ID: 35757301
[TBL] [Abstract][Full Text] [Related]
5. Interferon-α and its effects on cancer cell apoptosis.
Shi W; Yao X; Fu Y; Wang Y
Oncol Lett; 2022 Jul; 24(1):235. PubMed ID: 35720476
[TBL] [Abstract][Full Text] [Related]
6. CpG Oligodeoxynucleotides for Anticancer Monotherapy from Preclinical Stages to Clinical Trials.
Zhang Z; Kuo JC; Yao S; Zhang C; Khan H; Lee RJ
Pharmaceutics; 2021 Dec; 14(1):. PubMed ID: 35056969
[TBL] [Abstract][Full Text] [Related]
7. Tilsotolimod with Ipilimumab Drives Tumor Responses in Anti-PD-1 Refractory Melanoma.
Haymaker C; Johnson DH; Murthy R; Bentebibel SE; Uemura MI; Hudgens CW; Safa H; James M; Andtbacka RHI; Johnson DB; Shaheen M; Davies MA; Rahimian S; Chunduru SK; Milton DR; Tetzlaff MT; Overwijk WW; Hwu P; Gabrail N; Agrawal S; Doolittle G; Puzanov I; Markowitz J; Bernatchez C; Diab A
Cancer Discov; 2021 Aug; 11(8):1996-2013. PubMed ID: 33707233
[TBL] [Abstract][Full Text] [Related]
8. Characterization of genomic DNA of lactic acid bacteria for activation of plasmacytoid dendritic cells.
Horie A; Tomita Y; Ohshio K; Fujiwara D; Fujii T
BMC Microbiol; 2019 May; 19(1):88. PubMed ID: 31060586
[TBL] [Abstract][Full Text] [Related]
9. Bovine toll-like receptor 9: a comparative analysis of molecular structure, function and expression.
Griebel PJ; Brownlie R; Manuja A; Nichani A; Mookherjee N; Popowych Y; Mutwiri G; Hecker R; Babiuk LA
Vet Immunol Immunopathol; 2005 Oct; 108(1-2):11-6. PubMed ID: 16098606
[TBL] [Abstract][Full Text] [Related]
10. Synthetic agonists of Toll-like receptors 7, 8 and 9.
Agrawal S; Kandimalla ER
Biochem Soc Trans; 2007 Dec; 35(Pt 6):1461-7. PubMed ID: 18031246
[TBL] [Abstract][Full Text] [Related]
11. Impact of secondary structure of toll-like receptor 9 agonists on interferon alpha induction.
Yu D; Putta MR; Bhagat L; Dai M; Wang D; Trombino AF; Sullivan T; Kandimalla ER; Agrawal S
Antimicrob Agents Chemother; 2008 Dec; 52(12):4320-5. PubMed ID: 18852281
[TBL] [Abstract][Full Text] [Related]
12. Immunomodulatory oligonucleotides containing a cytosine-phosphate-2'-deoxy-7-deazaguanosine motif as potent toll-like receptor 9 agonists.
Kandimalla ER; Bhagat L; Li Y; Yu D; Wang D; Cong YP; Song SS; Tang JX; Sullivan T; Agrawal S
Proc Natl Acad Sci U S A; 2005 May; 102(19):6925-30. PubMed ID: 15860583
[TBL] [Abstract][Full Text] [Related]
13. Cross-talk between toll-like receptors 5 and 9 on activation of human immune responses.
Merlo A; Calcaterra C; Mènard S; Balsari A
J Leukoc Biol; 2007 Sep; 82(3):509-18. PubMed ID: 17586660
[TBL] [Abstract][Full Text] [Related]
14. Novel oligodeoxynucleotide agonists of TLR9 containing N3-Me-dC or N1-Me-dG modifications.
Putta MR; Zhu F; Li Y; Bhagat L; Cong Y; Kandimalla ER; Agrawal S
Nucleic Acids Res; 2006; 34(11):3231-8. PubMed ID: 16798912
[TBL] [Abstract][Full Text] [Related]
15. Impact of modifications of heterocyclic bases in CpG dinucleotides on their immune-modulatory activity.
Vollmer J; Weeratna RD; Jurk M; Davis HL; Schetter C; Wüllner M; Wader T; Liu M; Kritzler A; Krieg AM
J Leukoc Biol; 2004 Sep; 76(3):585-93. PubMed ID: 15218053
[TBL] [Abstract][Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
